biostudies-literatureUnknown113(11)Donskov F<h4>Background</h4>Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities.<h4>Methods</h4>In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), neutropenia (grade ⩾2), thrombocytopenia (grade ⩾2), hand-foot syndrome (grade >0), and asthenia/fatigue (grade >0)) were analysed in multivariate analyses of progression-free survival (PFS) and overall survival (OS) end points.<h4>Results</h4>On-treatment neutropenia and hypertension were associated with longer PFS (P=0.0276 and P<0.0001, respectively) and OS (P=0.0014 and P<0.0001, respectively), independent of baseline prognostic factors, including International Metastatic Renal CeBritish journal of cancer1571-80https://www.ebi.ac.uk/biostudies/studies/S-EPMC4705883biostudies-literatureSunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.PMC4705883Bjarnason GAMichaelson MDDavis MPGoldstein DLin XDonskov FCohen DPPuzanov IMotzer RJWiltshire RRini BIfalseSunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.<h4>Background</h4>Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities.<h4>Methods</h4>In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), neutropenia (grade ⩾2), thrombocytopenia (grade ⩾2), hand-foot syndrome (grade >0), and asthenia/fatigue (grade >0)) were analysed in multivariate analyses of progression-free survival (PFS) and overall survival (OS) end points.<h4>Results</h4>On-treatment neutropenia and hypertension were associated with longer PFS (P=0.0276 and P<0.0001, respectively) and OS (P=0.0014 and P<0.0001, respectively), independent of baseline prognostic factors, including International Metastatic Renal Ce2015-01-01T00:00:00Z2015 Dec2025-04-18T16:27:36.827Z2019-03-27T02:06:34ZS-EPMC47058832649222310.1038/bjc.2015.368